Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01054768|
Recruitment Status : Completed
First Posted : January 22, 2010
Last Update Posted : July 31, 2013
|Condition or disease||Intervention/treatment||Phase|
|Anemia, Sickle Cell||Dietary Supplement: alpha-lipoic acid and acetyl-L-carnitine Drug: Placebo||Phase 2|
People with sickle cell disease have more inflammation (a response of body tissues to injury or irritation) than people without sickle cell disease. This inflammation can be measured in the blood by checking the level of a protein called CRP as well as other changes we see in blood due to inflammation (such as changes in platelets and other cells). There is even more inflammation during sickle-related complications (like pain or acute chest syndrome). We want to test if inflammation in people with sickle cell disease can be reduced by the use of antioxidant compounds.
Antioxidants are nutrients (certain vitamins, minerals and enzymes) that can counteract the effects of oxidative stress arising from free radicals in our cells. The formation of free radicals is a normal cell process, but uncontrolled oxidative stress can cause problems for us. One such harmful problem is inflammation.
We know from other research studies that antioxidants help with some conditions related to inflammation. In this study the antioxidant being tested is a combination of alpha-lipoic acid and acetyl-L-carnitine, both of which are natural parts of many of the foods we eat and are needed by our cells to make energy from food.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||42 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease|
|Study Start Date :||August 2009|
|Actual Primary Completion Date :||April 2013|
|Actual Study Completion Date :||April 2013|
U.S. FDA Resources
Experimental: alpha-lipoic acid and acetyl-L-carnitine
LA and ALCAR 1400 mg tablet twice a day for 6 months.
Dietary Supplement: alpha-lipoic acid and acetyl-L-carnitine
none to report
Other Name: Juvenon
Placebo Comparator: Placebo
1400 mg placebo tablet twice a day for 6 months.
none to report
- C-Reactive Protein [ Time Frame: 6 months ]
- Relation between oxidative stress, inflammation and antioxidant therapy [ Time Frame: 6 months ]
- Change in inflammatory pathways in response to antioxidant therapy [ Time Frame: 6 months ]
- Change in frequency of pain episodes with antioxidant therapy [ Time Frame: 6 months ]
- Quality of life assessments on antioxidant therapy [ Time Frame: 6 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01054768
|United States, California|
|Children's Hospital & Research Center Oakland|
|Oakland, California, United States, 94609|
|Principal Investigator:||Elliott Vichinsky, MD||Children's Hospital & Research Center Oakland|
|Study Chair:||Bruce N. Ames, PhD||Children's Hospital & Research Center Oakland|
|Study Director:||Ashutosh Lal, M.D.||Children's Hospital & Research Center Oakland|